Screener
BridgeBio Pharma BBIO Available For Sale Securities Debt Securities Current
Available For Sale Securities Debt Securities Current at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $879,891 | $570,119 |
| Marketable securities | 60,295 | 17,363 |
| Accounts receivable, net | 205,226 | 139,444 |
| Inventories | 32,980 | 26,753 |
| Prepaid expenses and other current assets | 62,914 | 44,070 |
| Total current assets | 1,241,306 | 797,749 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's available for sale securities debt securities current?
- BridgeBio Pharma (BBIO) reported available for sale securities debt securities current of $60.3M in Q1 2026.
Ask your AI about BridgeBio Pharma's available for sale securities debt securities current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude